Impacting News
Premium
Bristol-Myers Squibb: Deucravacitinib Demonstrates Promising Results in Treating Systemic Lupus Erithematosus
Bristol-Myers Squibb Product Deucravacitinib Bristol-Myers Squibb ( BMY ) product deucravacitinib has demonstrated positive results from the Phase 2 PAISLEY study in comparison to placebo in patients...
P
Prohost Biotech
1 min read
1
0
Unlock Premium Content
This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.
Unlimited articles
Expert analysis
Research reports
Comments (0)
Please sign in to join the discussion